Compare Stocks: KZR, RNAC, ADCT, and ARTV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.41 -0.4%	$1.39	$0.78 ▼ $4.98	$197.63M	1.82	1.38 million shs	641,371 shs
ARTV Artiva Biotherapeutics	$3.96 -0.1%	$6.80	$2.96 ▼ $14.53	$195.50M	2.67	481,036 shs	376,278 shs
KZR Kezar Life Sciences	$7.29	$7.16	$3.53 ▼ $7.55	$53.86M	0.4	125,152 shs	616,000 shs
RNAC Cartesian Therapeutics	$6.32 -0.6%	$7.20	$5.60 ▼ $11.00	$192.76M	0.74	191,128 shs	27,633 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	-11.91%	-14.07%	-16.62%	+39.80%	-65.27%
ARTV Artiva Biotherapeutics	-2.70%	-4.12%	-37.04%	-65.41%	-0.50%
KZR Kezar Life Sciences	0.00%	0.00%	0.00%	0.00%	+18.34%
RNAC Cartesian Therapeutics	-7.56%	-6.19%	-3.20%	-28.05%	-16.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.41 -0.4%	$1.39	$0.78 ▼ $4.98	$197.63M	1.82	1.38 million shs	641,371 shs
ARTV Artiva Biotherapeutics	$3.96 -0.1%	$6.80	$2.96 ▼ $14.53	$195.50M	2.67	481,036 shs	376,278 shs
KZR Kezar Life Sciences	$7.29	$7.16	$3.53 ▼ $7.55	$53.86M	0.4	125,152 shs	616,000 shs
RNAC Cartesian Therapeutics	$6.32 -0.6%	$7.20	$5.60 ▼ $11.00	$192.76M	0.74	191,128 shs	27,633 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	-11.91%	-14.07%	-16.62%	+39.80%	-65.27%
ARTV Artiva Biotherapeutics	-2.70%	-4.12%	-37.04%	-65.41%	-0.50%
KZR Kezar Life Sciences	0.00%	0.00%	0.00%	0.00%	+18.34%
RNAC Cartesian Therapeutics	-7.56%	-6.19%	-3.20%	-28.05%	-16.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	2.33	Hold	$5.00	255.87% Upside
ARTV Artiva Biotherapeutics	2.14	Hold	$24.80	527.05% Upside
KZR Kezar Life Sciences	1.00	Sell	N/A	N/A
RNAC Cartesian Therapeutics	2.57	Moderate Buy	$32.60	415.82% Upside

Current Analyst Ratings Breakdown

Latest KZR, RNAC, ADCT, and ARTV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/29/2026	ARTV Artiva Biotherapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Hold	$4.00
10/27/2026	ARTV Artiva Biotherapeutics	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Hold
10/27/2026	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Hold
10/27/2026	ARTV Artiva Biotherapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Neutral	$4.00
10/19/2026	ARTV Artiva Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	ADCT ADC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/2/2026	ARTV Artiva Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/2/2026	ARTV Artiva Biotherapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$40.00
9/30/2026	RNAC Cartesian Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$25.00
9/29/2026	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$40.00
9/9/2026	RNAC Cartesian Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)

(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$81.36M	2.43	N/A	N/A	($1.77) per share	-0.79
ARTV Artiva Biotherapeutics	$250K	781.98	N/A	N/A	$6.49 per share	0.61
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	$9.57 per share	N/A
RNAC Cartesian Therapeutics	$2.80M	68.84	N/A	N/A	($4.28) per share	-1.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$142.62M	-$0.52	N/A	N/A	N/A	-95.73%	N/A	-28.26%	N/A
ARTV Artiva Biotherapeutics	-$83.86M	-$2.98	N/A	N/A	N/A	N/A	-45.32%	-41.38%	N/A
KZR Kezar Life Sciences	-$56.03M	-$6.17	N/A	N/A	N/A	N/A	-55.42%	-47.87%	N/A
RNAC Cartesian Therapeutics	-$130.30M	-$4.94	N/A	N/A	N/A	-8,550.65%	N/A	-23.63%	N/A

Latest KZR, RNAC, ADCT, and ARTV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	ADCT ADC Therapeutics	-$0.2125	-$0.16	+$0.0525	-$0.16	$18.70 million	$21.72 million
11/9/2026	Q3 2026	ARTV Artiva Biotherapeutics	-$0.5467	-$0.56	-$0.0133	-$0.56	N/A	N/A
11/5/2026	Q3 2026	RNAC Cartesian Therapeutics	-$1.01	-$0.38	+$0.63	-$0.38	$0.16 million	N/A
8/13/2026	Q2 2026	ADCT ADC Therapeutics	-$0.2160	-$0.11	+$0.1060	-$0.11	$18.89 million	$19.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	3.05	2.97
ARTV Artiva Biotherapeutics	N/A	19.88	24.16
KZR Kezar Life Sciences	N/A	11.52	11.52
RNAC Cartesian Therapeutics	N/A	8.38	8.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
ARTV Artiva Biotherapeutics	N/A
KZR Kezar Life Sciences	67.90%
RNAC Cartesian Therapeutics	86.95%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.10%
ARTV Artiva Biotherapeutics	1.80%
KZR Kezar Life Sciences	10.40%
RNAC Cartesian Therapeutics	37.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	191	140.66 million	121.16 million	Optionable
ARTV Artiva Biotherapeutics	134	49.43 million	48.54 million	Optionable
KZR Kezar Life Sciences	60	7.39 million	6.70 million	Not Optionable
RNAC Cartesian Therapeutics	75	30.50 million	19.16 million	Optionable

KZR, RNAC, ADCT, and ARTV Headlines

Recent News About These Companies

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Stock Has Consensus Target Price of $32.60 According to Brokerages

November 12 at 3:28 AM | americanbankingnews.com

FY2026 Earnings Forecast for RNAC Issued By HC Wainwright

November 12 at 1:28 AM | americanbankingnews.com

Wall Street Analysts See a 379.63% Upside in Cartesian Therapeutics, Inc. (RNAC): Can the Stock Really Move This High?

November 10 at 10:56 AM | zacks.com

HC Wainwright Has Optimistic Opinion of RNAC FY2026 Earnings

November 10 at 6:11 AM | marketbeat.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Stock Has Consensus Target Price of $32.60

November 7, 2026 | marketbeat.com

Cartesian Therapeutics (NASDAQ:RNAC) Stock Price Crosses Above 50 Day Moving Average - What's Next?

November 7, 2026 | marketbeat.com

Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

November 5, 2026 | globenewswire.com

Cartesian Therapeutics Announces New Employment Inducement Grant

November 3, 2026 | globenewswire.com

Cartesian: Maintaining 'Buy' On Descartes-08 MG Data Release And CAR-T Agreement

October 29, 2026 | seekingalpha.com

Cartesian Therapeutics (RNAC) Projected to Announce Quarterly Earnings on Thursday

October 29, 2026 | marketbeat.com

Cartesian Therapeutics Announces New Employment Inducement Grants - October 2, 2026

October 4, 2026 | biospace.comB

Cartesian Therapeutics Announces New Employment Inducement Grants

October 2, 2026 | globenewswire.com

Cartesian Reports Positive Phase 2 Retreatment Data For Descartes-08

September 29, 2026 | rttnews.com

Cartesian's Descartes-08 Shows Durable Responses In Myasthenia Gravis

September 29, 2026 | rttnews.com

Cartesian Therapeutics Reports Positive Retreatment Data for Descartes-08 in Generalized Myasthenia Gravis

September 29, 2026 | quiverquant.comQ

Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis

September 29, 2026 | globenewswire.com

Cartesian Therapeutics Announces New Employment Inducement Grants

September 8, 2026 | globenewswire.com

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

September 3, 2026 | globenewswire.com

Cantor Fitzgerald Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)

August 9, 2026 | theglobeandmail.com

Cartesian Therapeutics Announces New Employment Inducement Grants

August 7, 2026 | globenewswire.com

Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZR, RNAC, ADCT, and ARTV Company Descriptions

ADC Therapeutics NYSE:ADCT

$1.40 -0.01 (-0.35%)

As of 12:53 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Artiva Biotherapeutics NASDAQ:ARTV

$3.96 -0.01 (-0.13%)

As of 12:54 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Kezar Life Sciences NASDAQ:KZR

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Cartesian Therapeutics NASDAQ:RNAC

$6.32 -0.04 (-0.63%)

As of 12:53 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KZR, RNAC, ADCT, and ARTV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KZR, RNAC, ADCT, and ARTV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KZR, RNAC, ADCT, and ARTV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZR, RNAC, ADCT, and ARTV Company Descriptions

ADC Therapeutics NYSE:ADCT

Artiva Biotherapeutics NASDAQ:ARTV

Kezar Life Sciences NASDAQ:KZR

Cartesian Therapeutics NASDAQ:RNAC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KZR, RNAC, ADCT, and ARTV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KZR, RNAC, ADCT, and ARTV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KZR, RNAC, ADCT, and ARTV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZR, RNAC, ADCT, and ARTV Company Descriptions

ADC Therapeutics NYSE:ADCT

Artiva Biotherapeutics NASDAQ:ARTV

Kezar Life Sciences NASDAQ:KZR

Cartesian Therapeutics NASDAQ:RNAC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools